dc.contributor
Institut Català de la Salut
dc.contributor
[Biondetti E, Gaurav R] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France. ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France. [Santin MD, Valabrègue R] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France. [Mangone G] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, Paris, France. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Paris, France. [Pyatigorskaya N] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neuroradiology, Paris, France. [Vila M] Grup de Recerca en Malalties Neurodegeneratives, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED). Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Biondetti, Emma
dc.contributor.author
Santin, Mathieu
dc.contributor.author
Valabrègue, Romain
dc.contributor.author
Mangone, Graziella
dc.contributor.author
Gaurav, Rahul
dc.contributor.author
Pyatigorskaya, Nadya
dc.contributor.author
Vila Bover, Miquel
dc.date.accessioned
2025-10-24T08:52:32Z
dc.date.available
2025-10-24T08:52:32Z
dc.date.issued
2022-06-14T07:44:29Z
dc.date.issued
2022-06-14T07:44:29Z
dc.identifier
Biondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease. Brain. 2021 Oct;144(10):3114–25.
dc.identifier
https://hdl.handle.net/11351/7678
dc.identifier
10.1093/brain/awab191
dc.identifier
000733375400026
dc.identifier.uri
http://hdl.handle.net/11351/7678
dc.description.abstract
Dopamine transporter; Iron; Neuromelanin
dc.description.abstract
Transportador de dopamina; Hierro; Neuromelanina
dc.description.abstract
Transportador de dopamina; Ferro; Neuromelanina
dc.description.abstract
In Parkinson’s disease, there is a progressive reduction in striatal dopaminergic function, and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition in the substantia nigra. We tested the hypothesis of a relationship between impairment of the dopaminergic system and changes in the iron metabolism. Based on imaging data of patients with prodromal and early clinical Parkinson’s disease, we assessed the spatiotemporal ordering of such changes and relationships in the sensorimotor, associative and limbic territories of the nigrostriatal system.
Patients with Parkinson’s disease (disease duration < 4 years) or idiopathic REM sleep behaviour disorder (a prodromal form of Parkinson’s disease) and healthy controls underwent longitudinal examination (baseline and 2-year follow-up). Neuromelanin and iron sensitive MRI and dopamine transporter single-photon emission tomography were performed to assess nigrostriatal levels of neuromelanin, iron, and dopamine. For all three functional territories of the nigrostriatal system, in the clinically most and least affected hemispheres separately, the following was performed: cross-sectional and longitudinal intergroup difference analysis of striatal dopamine and iron, and nigral neuromelanin and iron; in Parkinson’s disease patients, exponential fitting analysis to assess the duration of the prodromal phase and the temporal ordering of changes in dopamine, neuromelanin or iron relative to controls; and voxel-wise correlation analysis to investigate concomitant spatial changes in dopamine-iron, dopamine-neuromelanin and neuromelanin-iron in the substantia nigra pars compacta.
The temporal ordering of dopaminergic changes followed the known spatial pattern of progression involving first the sensorimotor, then the associative and limbic striatal and nigral regions. Striatal dopaminergic denervation occurred first followed by abnormal iron metabolism and finally neuromelanin changes in the substantia nigra pars compacta, which followed the same spatial and temporal gradient observed in the striatum but shifted in time.
In conclusion, dopaminergic striatal dysfunction and cell loss in the substantia nigra pars compacta are interrelated with increased nigral iron content.
dc.description.abstract
The ICEBERG study was funded by grants from the Investissements d'Avenir, IAIHU-06 (Paris Institute of Neurosciences – IHU), ANR-11-INBS-0006, Fondation d’Entreprise EDF, Biogen Inc., Fondation Thérèse and René Planiol, Fondation Saint Michel, Unrestricted support for Research on Parkinson’s disease from Energipole (M. Mallart), M.Villain and Société Française de Médecine Esthétique (M. Legrand).
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Oxford University Press
dc.relation
Brain;144(10)
dc.relation
https://doi.org/10.1093/brain/awab191
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Parkinson, Malaltia de - Imatgeria per ressonància magnètica
dc.subject
Neurones dopaminèrgiques
dc.subject
DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease
dc.subject
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Amino Acids, Aromatic::Tyrosine::Melanins
dc.subject
CHEMICALS AND DRUGS::Organic Chemicals::Amines::Biogenic Amines::Biogenic Monoamines::Dopamine
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::aminoácidos::aminoácidos cíclicos::aminoácidos aromáticos::tirosina::melaninas
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::aminas::aminas biógenas::monoaminas biógenas::dopamina
dc.title
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion